
MEDPACE HOLDINGS INC
MEDPNASDAQTrading Snapshot
- Day Range
- $603.09 โ $611.03
- 52-Week Range
- $373.00 โ $677.90
- Volume
- $3.08B
- Avg Volume
- $3.54B
- Shares Outstanding
- 27.9M
- Next Earnings
- Oct 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.53B
- Last Q Revenue
- $707M
- P/E Ratio
- 34.2
- P/S Ratio
- 6.0x
- EPS (TTM)
- $17.05
- Dividend Yield
- โ
Why Investors Own MEDP
- โHigh-growth profile โ revenue up +34.0% YoY with expanding US Equity exposure.
- โHealthy economics โ 63% gross margin and 29% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About MEDPACE HOLDINGS INC
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates

CON or MEDP: Which Is the Better Value Stock Right Now?
CON vs. MEDP: Which Stock Is the Better Value Option?

PBH Stock Up on Q1 Earnings and Revenue Beat, Fiscal '27 View Raised
Prestige Consumer's Q1 earnings and revenues outpace estimates as acquisitions boost its fiscal 2027 outlook despite margin pressure.

Medpace (MEDP) Just Flashed Golden Cross Signal: Do You Buy?
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

STE Q1 Earnings Beat, Revenues Miss, Stock Dips in Aftermarket Trading
STERIS beats fiscal Q1 earnings estimates as sales rise 7.3%, but a modest revenue miss sends shares 2.4% lower after hours.

Is MEDP Worth Buying as Growth Collides With a Premium Valuation?
Medpace pairs double-digit growth, record awards and a strong balance sheet with a rich valuation, raising the question of whether the premium already prices in its outlook.

CRL Q2 Earnings and Revenues Top, '26 View Up, Stock Up in Pre-Market
Charles River beats Q2 earnings and revenue estimates, raises 2026 outlook and gains 7.9% in pre-market trading.